首页 >
法规速递
-
Document: Applications for new human medicines under evaluation: September 2025-2025/9/1
2025-09-02查看详情 > -
Page: PRAC Interest Group on Measuring the Impact of Pharmacovigilance Activities (PRAC IG Impact)-2025/10/3
2025-10-08查看详情 > -
Page: Switching between superiority and non-inferiority - Scientific guideline-2025/11/13
2025-11-14查看详情 > -
Document: Mandate, objectives and rules of procedure for the Cancer Medicines Forum-2025/12/9
2025-12-10查看详情 > -
Document: European Union example instances - E2B(R3) testing files-2026/1/21
2026-01-22查看详情 > -
Page: List of medicines under additional monitoring-2026/2/25
2026-02-27查看详情 > -
Page: Biosimilar medicines: Overview-2026/3/27
2026-03-30查看详情 > -
Enforcement Priorities for Certain New Tobacco Products Marketed Without Premarket Authorization-2026/5/8
2026-05-09查看详情 > -
Regulatory and procedural guideline: European Medicines Agency pre-authorisation procedural advice for users of the centralised procedure: document with tracked changes-2023/4/25
2023-04-26查看详情 > -
Draft Guidance: Communications From Firms to Health Care Providers Regarding Scientific Information on Unapproved Uses of Approved/Cleared Medical Products Questions and Answers-2023/10/23
2023-11-07查看详情 >
